2026 Hinrich Gronemeyer: Biology and Biochemistry Researcher – H-Index, Publications & Awards

Discipline name	D-Index	World Ranking	Current World Ranking	National Ranking	Current National Ranking	Publications	Citations
Biology and Biochemistry	94	1962	1772	37	35	304	48128

Research.com Recognitions

2023 - Research.com Biology and Biochemistry in France Leader Award
Member of the European Molecular Biology Organization (EMBO)
Member of the European Molecular Biology Organization (EMBO)
Member of the European Molecular Biology Organization (EMBO)

Overview

Hinrich Gronemeyer is affiliated with the Institute of Genetics and Molecular and Cellular Biology in France. Their research primarily spans the field of Biochemistry, Genetics, and Molecular Biology, with a notable focus on Molecular Biology, Cancer Research, Oncology, Aging, and Genetics as subfields.

The scientist's research topics cover several areas, including:

Pluripotent Stem Cells Research
Cancer Genomics and Diagnostics
Histone Deacetylase Inhibitors Research
Epigenetics and DNA Methylation
CRISPR and Genetic Engineering
Genetics, Aging, and Longevity in Model Organisms
RNA Interference and Gene Delivery

Hinrich Gronemeyer has published extensively in various venues, with frequent contributions to:

Faculty Opinions - Post-Publication Peer Review of the Biomedical Literature
International Journal of Cancer
bioRxiv (Cold Spring Harbor Laboratory)
Cell Death and Differentiation
iScience

Their notable recent papers include:

"Apoptotic cell death in disease-Current understanding of the NCCD 2023" (2023), published in Cell Death and Differentiation
"CDYL2 Epigenetically Regulates MIR124 to Control NF-κB/STAT3-Dependent Breast Cancer Cell Plasticity" (2020), published in iScience
"Comparative roadmaps of reprogramming and oncogenic transformation identify Bcl11b and Atoh8 as broad regulators of cellular plasticity" (2022), published in Nature Cell Biology
"Activation Function 2 in the Human Androgen Receptor Ligand Binding Domain Mediates Interdomain Communication with the NH 2 -terminal Domain" (2021), published in UNC Libraries
"Complexity against current cancer research: Are we on the wrong track?" (2021), published in International Journal of Cancer

Frequent collaborators in their research include:

Marco Antonio Mendoza-Parra, with five co-authored works
Lucia Altucci, with three co-authored works
Maha Siouda, with three co-authored works
Benjamin Gibert, with three co-authored works
Peter Mulligan, with three co-authored works

Hinrich Gronemeyer is recognized as a member of the European Molecular Biology Organization (EMBO).

Best Publications

Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018

Lorenzo Galluzzi;Ilio Vitale;Stuart A. Aaronson;John M. Abrams

6452
Citations
Two distinct estrogen‐regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B.

P Kastner;A Krust;B Turcotte;U Stropp

1956
Citations
Principles for modulation of the nuclear receptor superfamily

Hinrich Gronemeyer;Jan Åke Gustafsson;Vincent Laudet

1505
Citations
Crystal structure of the ligand-binding domain of the human nuclear receptor RXR-alpha.

William Bourguet;Marc Ruff;Pierre Chambon;Hinrich Gronemeyer

1502
Citations
Crystal structure of the RAR-gamma ligand-binding domain bound to all-trans retinoic acid.

Jean-Paul Renaud;Natacha Rochel;Marc Ruff;Valéria Vivat

1429
Citations
TIF2, a 160 kDa transcriptional mediator for the ligand-dependent activation function AF-2 of nuclear receptors

Johannes J. Voegel;Matthias J.S. Heine;Christina Zechel;Pierre Chambon

1360
Citations
A canonical structure for the ligand-binding domain of nuclear receptors.

Jean Marie Wurtz;William Bourguet;Jean Paul Renaud;Valerie Vivat

1200
Citations
Essential versus accessory aspects of cell death: recommendations of the NCCD 2015

L. Galluzzi;J. M. Bravo-San Pedro;I. Vitale;S. A. Aaronson

1178
Citations
A unified nomenclature system for the nuclear receptor superfamily

J. Auwerx;E. Baulieu;M. Beato;M. Becker-Andre

1159
Citations
THE NUCLEAR RECEPTOR LIGAND-BINDING DOMAIN : STRUCTURE AND FUNCTION

Dino Moras;Hinrich Gronemeyer

1087
Citations
The promise of retinoids to fight against cancer

Lucia Altucci;Lucia Altucci;Hinrich Gronemeyer

985
Citations
Senescence-associated reprogramming promotes cancer stemness

Maja Milanovic;Dorothy N. Y. Fan;Dimitri Belenki;J. Henry M. Däbritz

910
Citations
Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes

L. Galluzzi;L. Galluzzi;L. Galluzzi;S. A. Aaronson;J. Abrams;E. S. Alnemri

823
Citations
The N-terminal part of TIF1, a putative mediator of the ligand-dependent activation function (AF-2) of nuclear receptors, is fused to B-raf in the oncogenic protein T18.

B. Le Douarin;C. Zechel;J.M. Garnier;Y. Lutz

751
Citations
Steroid hormone receptors compete for factors that mediate their enhancer function

Marc-Etienne Meyer;Hinrich Gronemeyer;Hinrich Gronemeyer;Bernard Turcotte;Bernard Turcotte;Marie-Thérèse Bocquel;Marie-Thérèse Bocquel

706
Citations
Nuclear receptor ligand-binding domains: three-dimensional structures, molecular interactions and pharmacological implications

William Bourguet;Pierre Germain;Hinrich Gronemeyer

640
Citations
Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells.

Angela Nebbioso;Nicole Clarke;Emilie Voltz;Emmanuelle Germain

638
Citations
The coactivator TIF2 contains three nuclear receptor-binding motifs and mediates transactivation through CBP binding-dependent and -independent pathways.

Johannes J. Voegel;Matthias J.S. Heine;Marc Tini;Valérie Vivat

624
Citations
RAR and RXR modulation in cancer and metabolic disease

Lucia Altucci;Mark D Leibowitz;Kathleen M Ogilvie;Angel R de Lera

604
Citations
International Union of Pharmacology. LXIII. Retinoid X Receptors

Pierre Germain;Pierre Chambon;Gregor Eichele;Ronald M. Evans

577
Citations